Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 9Active not recruiting 6Completed 3Terminated 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Genitourinary 65CNS 64Breast 59Gastrointestinal 53Thoracic 26Lymphoid 25Sarcoma 23Gynecologic 18Head & Neck 17Tumor-Agnostic 11Dermatologic 10Endocrine 9Other solid neoplasm 8Other hematologic neoplasm 7Plasma cell 5NET 3Myeloid 2Other 1

Conditions

Neuroendocrine Tumors 2Somatostatinoma 1Neuroblastoma 1Medulloblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Everolimus 19lutetium Lu 177 dotatate 8Octreotide 8lanreotide 7pasireotide 6Temozolomide 6Sunitinib 6pembrolizumab 5gallium Ga 68 dotatate 5Positron Emission Tomography Computed Tomography 5surufatinib 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Magnetic Resonance Spectroscopy 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Magnetic Resonance Spectroscopy × NET × Clear all
NCT01423734 2023-01-23

The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases

Memorial Sloan Kettering Cancer Center

Completed
20 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT01869725 2021-09-22

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

University of Iowa

Phase 2 Completed
68 enrolled 8 charts
CNSEndocrineNET

Medulloblastoma, Neuroblastoma, Somatostatinoma, Neuroendocrine Tumors

NCT03948841 2019-05-14

NETMRI

CHU de Reims

Completed
41 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡